Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00390871 · ClinicalTrials.gov registry record · Phase 2

Acute Neurological ICU Sedation Trial (ANIST)

A Phase 2 study of Sedation, sponsored by Johns Hopkins University.

Completed
Registry status
Phase 2
Development phase
35
Enrollment target
1
Study location

NCT00390871: Completed Phase 2 study of Sedation, sponsored by Johns Hopkins University.

NCT00390871 is a Phase 2 study of Sedation that has completed, run by Johns Hopkins University. The registered enrollment target is 35 participants, below the 100,183-participant average among 12 other Sedation trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00390871, a Phase 2 study of Sedation, has completed, sponsored by Johns Hopkins University.

COMPLETED
Registry status
Phase 2
Development phase
35 participants
Enrollment target
1
Study location

Study Summary

Dexmedetomidine (Precedex, Hospira) is a "super" selective alpha2-agonist - 8-10x more avid binding to alpha2 receptors than clonidine - and may have particularly favorable characteristics as a continuous i.v. infusion sedative for critically ill neuroscience patients. Its combination of anxiolysis, analgesia, without undue lethargy may make it an ideal agent where frequent neurological examinations are important. Unclear, however, is whether Precedex is superior to current common i.v. sedation protocols, and if there are any undue concerns of this agent on cerebral physiology and cortical stimulation.

Primary Outcome

Cognitive assessment tool

Conditions Studied

Interventions

  • DRUG Fentanyl
  • DRUG Fentanyl/Dexmedetomidine
  • DRUG Fentanyl/Propofol

Study Locations (1)

Maryland

  • Johns Hopkins University - Baltimore

Trial Details

FieldValue
Enrollment Target 35 participants
Start Date 2005-05
Est. Completion 2007-12
Phase Phase 2
Johns Hopkins University

1,448 total trials

What the finished NCT00390871 record still lists

NCT00390871 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 100,183-participant average among 12 other Sedation trials with a reported enrollment target (100% lower).

The record links to 1 condition, with Sedation appearing as the primary indexed condition, and to 3 interventions - of which Fentanyl is the first listed.

NCT00390871 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT00390871 about?

NCT00390871 is a clinical study titled "Acute Neurological ICU Sedation Trial (ANIST)". Dexmedetomidine (Precedex, Hospira) is a "super" selective alpha2-agonist - 8-10x more avid binding to alpha2 receptors than clonidine - and may have particularly favorable characteristics as a continuous i.v. infusion sedative for critically ill neuroscience patients. Its combination of anxiolysis,...

What is the current status of trial NCT00390871?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2005-05. Estimated completion is 2007-12.

What conditions does trial NCT00390871 study?

This clinical trial studies the following conditions: Sedation.

What interventions are being tested in trial NCT00390871?

The interventions under investigation include: Fentanyl (DRUG), Fentanyl/Dexmedetomidine (DRUG), Fentanyl/Propofol (DRUG).

Who is sponsoring clinical trial NCT00390871?

This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00390871 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Sedation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00390871's enrollment target sits among peer trials

35 11th of 12 higher than 2 of 12 other Sedation trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Sedation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01697371 · 35 participants · NA

    Proton Therapy in the Treatment of Liver Metastases

  • NCT01940757 · 35 participants · Phase 1

    Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae

  • NCT02235857 · 35 participants · NA

    Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children

  • NCT02637934 · 35 participants · Phase 1

    Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00390871, the US trial registry maintained by the National Library of Medicine. NCT00390871 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.